BACKGROUND The goal of cervical cancer screening is to identify dysplastic lesions for subsequent excision in order to prevent invasive disease. There is clinical equipoise, on how to best follow women for disease surveillance after treatment with some Canadian provinces exclusively performing colposcopy and some utilizing Human Papilloma Virus (HPV) testing in addition to cervical cytology. Loop Electrosurgical Excision Procedure (LEEP) is used to treat pre-invasive HPV-mediated disease and patients are typically followed for 12 months after disease excision. This study aims to quantify the prevalence of high-grade disease at the time of the second follow-up colposcopy visit, in a practice setting that utilizes laser ablation in addition to LEEP. METHODS In a retrospective cohort study, consecutive patient charts were accessed through the electronic medical record system, ARIA, at the Tom Baker Cancer Centre, in Calgary, Alberta, from January 2010 to December 2015. Data was extracted and a REDCap database was used to compile pertinent information from charts meeting inclusion criteria. Descriptive and analytic statistics were performed. RESULTS Of the 303 patients identified, 221 patients met inclusion criteria. 86% of these patients met discharge criteria from colposcopy after the second follow up visit. 31 (14%) were seen in a subsequent visit for abnormal findings. Of these, 7 (3.2%) underwent further treatment for high-grade disease/Cervical Intraepithelial Neoplasia (CIN 2/3). Of the 31, 23 (10.6%) had a third - negative - visit, resulting in discharge from colposcopy. One patient had a repeat LEEP for persistent Low-Grade Squamous Intraepithelial Lesion (LSIL). CONCLUSION In summary, our data demonstrates a prevalence of 3.2% of high-grade disease at the time of a second colposcopic follow up visit after treatment, in a setting which frequently utilizes laser ablation in combination with LEEP, for large lesions. This recurrence rate is consistent with most published literature on recurrence rates of CIN2/3.

中文翻译：

---

确定循环电外科切除程序（LEEP）后的短期疾病复发。

背景技术子宫颈癌筛查的目的是识别发育不良的病变以便随后切除，以防止侵袭性疾病。关于如何最好地利用阴道镜在加拿大的一些省进行治疗，以及在宫颈细胞学之外还利用人乳头瘤病毒（HPV）测试进行治疗之后，如何最好地跟踪女性进行疾病监测的临床方法。循环电外科切除术（LEEP）用于治疗HPV介导的浸润前疾病，患者通常在疾病切除后被随访12个月。这项研究旨在量化在第二次随访阴道镜检查访视时高级别疾病的患病率，这是在除LEEP之外还利用激光消融的实践环境中进行的。方法在一项回顾性队列研究中，从2010年1月至2015年12月，通过位于艾伯塔省卡尔加里的汤姆贝克癌症中心的ARIA电子病历系统访问了连续的患者病历。提取了数据，并使用REDCap数据库汇编了满足纳入要求的病历中的相关信息标准。进行描述性和分析性统计。结果在确定的303例患者中，有221例符合纳入标准。第二次随访后，这些患者中有86％符合阴道镜出院标准。随后的随访中发现31例（14％）为异常发现。其中7例（3.2％）接受了进一步治疗，以治疗高级别疾病/宫颈上皮内瘤变（CIN 2/3）。在31名患者中，有23名（10.6％）进行了第三次阴性访视，导致阴道镜检查出院。一名患者因持续性低度鳞状上皮内病变（LSIL）重复进行了LEEP。结论总而言之，我们的数据表明，在大面积病变的治疗中，经常使用激光消融结合LEEP的情况下，在治疗后进行第二次阴道镜随访时，有3.2％的高危疾病患病率。该复发率与有关CIN2 / 3复发率的大多数公开文献一致。